JP7420554B2 - 滅菌密閉異種薬物送達デバイス - Google Patents
滅菌密閉異種薬物送達デバイス Download PDFInfo
- Publication number
- JP7420554B2 JP7420554B2 JP2019521012A JP2019521012A JP7420554B2 JP 7420554 B2 JP7420554 B2 JP 7420554B2 JP 2019521012 A JP2019521012 A JP 2019521012A JP 2019521012 A JP2019521012 A JP 2019521012A JP 7420554 B2 JP7420554 B2 JP 7420554B2
- Authority
- JP
- Japan
- Prior art keywords
- envelope
- drug
- item
- barrel
- delivery assembly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims description 133
- 229940079593 drug Drugs 0.000 claims description 130
- 230000005855 radiation Effects 0.000 claims description 64
- 239000011888 foil Substances 0.000 claims description 32
- 238000010894 electron beam technology Methods 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000012620 biological material Substances 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 20
- 239000012298 atmosphere Substances 0.000 claims description 14
- 235000000346 sugar Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 229940071643 prefilled syringe Drugs 0.000 claims description 11
- 239000011261 inert gas Substances 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 9
- 229940090047 auto-injector Drugs 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000004775 Tyvek Substances 0.000 claims description 4
- 229920000690 Tyvek Polymers 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 230000002009 allergenic effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000012503 blood component Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 238000013016 damping Methods 0.000 description 65
- 238000000034 method Methods 0.000 description 42
- 238000006073 displacement reaction Methods 0.000 description 37
- 239000012530 fluid Substances 0.000 description 33
- 230000001954 sterilising effect Effects 0.000 description 29
- 230000008569 process Effects 0.000 description 28
- 230000007246 mechanism Effects 0.000 description 25
- 238000004659 sterilization and disinfection Methods 0.000 description 25
- 210000003811 finger Anatomy 0.000 description 22
- 239000000463 material Substances 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 14
- 239000000306 component Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 9
- 150000008163 sugars Chemical class 0.000 description 9
- 230000037452 priming Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 5
- 230000005461 Bremsstrahlung Effects 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 230000002391 anti-complement effect Effects 0.000 description 3
- 108010008730 anticomplement Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004146 energy storage Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000016550 Complement Factor H Human genes 0.000 description 2
- 108010053085 Complement Factor H Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 102100026121 Flap endonuclease 1 Human genes 0.000 description 2
- 108050007570 GTP-binding protein Rad Proteins 0.000 description 2
- 101000913035 Homo sapiens Flap endonuclease 1 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100026386 Ribonuclease K6 Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- -1 methiplanol Chemical compound 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950000482 lampalizumab Drugs 0.000 description 1
- 108010032674 lampalizumab Proteins 0.000 description 1
- 229960004771 levobetaxolol Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/001—Apparatus specially adapted for cleaning or sterilising syringes or needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/087—Particle radiation, e.g. electron-beam, alpha or beta radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/14586—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of a flexible diaphragm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/1785—Syringes comprising radioactive shield means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/14—Means for controlling sterilisation processes, data processing, presentation and storage means, e.g. sensors, controllers, programs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/18—Aseptic storing means
- A61L2202/181—Flexible packaging means, e.g. permeable membranes, paper
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M2005/31588—Constructional features or modes of drive mechanisms for piston rods electrically driven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0486—Glucose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/09—Body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0272—Electro-active or magneto-active materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
例えば、本願は以下の項目を提供する。
(項目1)
薬物送達装置であって、
薬物を含有する及び薬物送達出口を有するチャンバと、
送達アセンブリであって、
前記出口に対して、前記チャンバに固定されるシャーシと、
前記出口を通って前記薬物を移動させるように、前記出口に対して移動するように構成される流体置換部材と、を含む、前記送達アセンブリと、
エンベロープであって、
前記シャーシを滅菌するように囲繞し、
化学滅菌から生じた残留物を包囲しない、前記エンベロープと、
を備える、前記薬物送達装置。
(項目2)
前記流体置換部材はピストンを備える、項目1に記載の装置。
(項目3)
前記流体置換部材はフラップを備える、項目1に記載の装置。
(項目4)
前記流体置換部材は弾性エネルギーストレージデバイスを備える、項目1に記載の装置。
(項目5)
前記流体置換部材は永久磁石を備える、項目1に記載の装置。
(項目6)
前記流体置換部材は電磁石を備える、項目1に記載の装置。
(項目7)
前記流体置換部材は膜を備える、項目1に記載の装置。
(項目8)
前記膜は拡張可能である、項目7に記載の装置。
(項目9)
前記チャンバは第1の減衰能力を有し、
前記送達アセンブリは第2の減衰能力を有し、
前記第1及び第2の電子ビームの減衰能力は異なる、
項目1に記載の装置。
(項目10)
前記チャンバは事前充填シリンジのバレル内に含まれる、項目1に記載の装置。
(項目11)
前記バレルはガラスを含む、項目10に記載の装置。
(項目12)
前記バレルはポリマーを含む、項目10に記載の装置。
(項目13)
前記出口は前記チャンバから離れるように延在する中心軸を有し、
前記送達アセンブリは前記軸の周りで回転対称ではない、
項目1に記載の装置。
(項目14)
前記送達アセンブリは自動注射器を含み、
前記チャンバは前記自動注射器のリザーバを含む、
項目1に記載の装置。
(項目15)
前記バレルはガラスを含む、項目14に記載の装置。
(項目16)
前記バレルはポリマーを含む、項目14に記載の装置。
(項目17)
前記薬物は3,000ダルトンより大きくない質量を有する分子を含む、項目1に記載の装置。
(項目18)
前記薬物は少なくとも3,000ダルトンであり、500,000ダルトンよりも大きくない質量を有する分子を含む、項目1に記載の装置。
(項目19)
前記薬物は少なくとも500,000ダルトンの質量を有する分子を含む、項目1に記載の装置。
(項目20)
前記薬物はタンパク質を含む、項目1に記載の装置。
(項目21)
前記薬物は糖を含む、項目1に記載の装置。
(項目22)
前記糖は約342gram/molである分子量を有する、項目21に記載の装置。
(項目23)
前記薬物は抗体を含む、項目1に記載の装置。
(項目24)
前記抗体はモノクローナル抗体である、項目23に記載の装置。
(項目25)
前記薬物は抗体断片を含む、項目1に記載の装置。
(項目26)
前記薬物は生物由来物質を含む、項目1に記載の装置。
(項目27)
前記生物由来物質はワクチンを含む、項目26に記載の装置。
(項目28)
前記生物由来物質は血液成分を含む、項目26に記載の装置。
(項目29)
前記生物由来物質は血液を含む、項目26に記載の装置。
(項目30)
前記生物由来物質はアレルギー性を含む、項目26に記載の装置。
(項目31)
前記生物由来物質は細胞を含む、項目26に記載の装置。
(項目32)
前記細胞は活動的である、項目31に記載の装置。
(項目33)
前記生物由来物質は遺伝子を含む、項目26に記載の装置。
(項目34)
前記生物由来物質は組織を含む、項目26に記載の装置。
(項目35)
前記組織は活動的である、項目34に記載の装置。
(項目36)
前記生物由来物質は核酸を含む、項目26に記載の装置。
(項目37)
前記生物由来物質はペプチド治療剤を含む、項目26に記載の装置。
(項目38)
前記エンベロープはスリーブを含む、項目1に記載の装置。
(項目39)
前記エンベロープは放射線検出器を含む、項目1に記載の装置。
(項目40)
前記エンベロープは、前記エンベロープの外側にあり及び前記エンベロープに隣接する大気に対して、不活性ガスが豊富な大気を含む、項目1に記載の装置。
(項目41)
前記不活性ガスは窒素N 2 を含む、項目40に記載の装置。
(項目42)
前記エンベロープの外側にあり及び前記エンベロープに隣接する大気中の化合物よりも濃い濃度において、前記エンベロープの内側に包囲される吸水性化合物をさらに含む、項目1に記載の装置。
(項目43)
前記エンベロープ内で包囲される気体酸素O 2 の濃度は、1ppm以下である、項目1に記載の装置。
(項目44)
前記エンベロープ内に包囲される気体水蒸気H 2 Oの濃度は、1ppm以下である、項目1に記載の装置。
(項目45)
前記エンベロープは、
質量伝送に不浸透性である第1の不浸透性部材と、
前記第1の不浸透性部材の反対にある、質量伝送に不浸透性である第2の不浸透性部材であって、前記第1及び第2の不浸透性部材が相互に密閉される、前記第2の不浸透性部材と、
を含む、項目1に記載の装置。
(項目46)
前記第1の不浸透性部材は、前記送達アセンブリを収容するように窪みがある、項目45に記載の装置。
(項目47)
前記第1の不浸透性部材は成形ポリマーを備える、項目46に記載の装置。
(項目48)
前記第2の不浸透性部材はホイルを含む、項目45に記載の装置。
(項目49)
前記第2の不浸透性部材は、商標TYVEKの下で販売されるホイルを含む、項目48に記載の装置。
(項目50)
前記第1の不浸透性部材はホイルを含み、
前記第2の不浸透性部材はホイルを含む、
項目45に記載の装置。
(項目51)
前記第1の不浸透性部材は前記送達アセンブリを収容するように窪みがあり、
前記第2の不浸透性部材は前記送達アセンブリを収容するように窪みがある、
項目45に記載の装置。
(項目52)
前記第1の不浸透性部材はシースを含み、
前記第2の不浸透性部材はキャップを含む、
項目45に記載の装置。
(項目53)
前記キャップはホイルを備える、項目52に記載の装置。
(項目54)
前記エンベロープはブリスターパックを含む、項目1に記載の装置。
(項目55)
前記残留物は蒸気を含む、項目1に記載の装置。
(項目56)
前記残留物は吸着分子を含む、項目1に記載の装置。
(項目57)
前記吸着分子は前記エンベロープ上に配置される、項目56に記載の装置。
(項目58)
前記吸着分子は前記送達アセンブリ上に配置される、項目56に記載の装置。
(項目59)
前記第1の減衰能力は、1よりも大きい倍数だけ前記第2の減衰能力よりも大きい、項目9に記載の装置。
(項目60)
前記エンベロープは、前記第1の減衰能力よりも50倍小さい第3の減衰能力を有する、項目9に記載の装置。
(項目61)
前記送達アセンブリは、
縦軸の周りに配置されるトロイダル状要素と、
前記縦軸の周りに配置されるシャフト要素と、
含む、項目9に記載の装置。
(項目62)
前記トロイダル状要素は、前記シャフトに対して前記縦軸の周りに回転可能である、項目61に記載の装置。
(項目63)
前記薬物及び前記バレルを中心に、前記第1の減衰能力よりも10倍小さい減衰能力を有するシースをさらに備える、項目9に記載の装置。
1次元線形質量減衰モデル
式中、
式中、Z1及びZ2が各々R1及びR2の材料の原子数であり、VEBはBの電圧である。したがって、方程式4に関して、以下のとおりである。
Claims (48)
- 薬物送達装置であって、前記薬物送達装置は、
チャンバを備えるバレルであって、前記チャンバは、薬物を含有し、前記チャンバは、薬物送達出口と第1の電子ビーム減衰能力とを有する、バレルと、
第2の電子ビーム減衰能力を有する送達アセンブリであって、前記送達アセンブリは、
接着剤によって前記バレルに固定されているシャーシであって、前記シャーシは、前記チャンバを全体的にまたは部分的に包囲するように構成されている、シャーシと、
前記出口を通って前記薬物を移動させるように、前記出口に対して移動するように構成されているプランジャロッドと
を含む、送達アセンブリと、
前記シャーシを滅菌するように囲繞するエンベロープと
を備え、
前記第1の電子ビーム減衰能力は、前記第2の電子ビーム減衰能力よりも大きい、薬物送達装置。 - 前記バレルは、事前充填シリンジのバレルである、請求項1に記載の装置。
- 前記バレルは、ガラスを含む、請求項2に記載の装置。
- 前記バレルは、ポリマーを含む、請求項2に記載の装置。
- 前記プランジャロッドは、軸に沿って移動可能であり、
前記送達アセンブリは、前記軸の周りで回転対称ではない、請求項1に記載の装置。 - 前記送達アセンブリは、自動注射器を含み、
前記チャンバは、前記自動注射器のリザーバを含む、請求項1に記載の装置。 - 前記バレルは、事前充填シリンジのバレルであり、前記バレルは、ガラスを含む、請求項6に記載の装置。
- 前記バレルは、事前充填シリンジのバレルであり、前記バレルは、ポリマーを含む、請求項6に記載の装置。
- 前記薬物は、3,000ダルトンより大きくない質量を有する分子を含む、請求項1に記載の装置。
- 前記薬物は、少なくとも3,000ダルトンであり、かつ、500,000ダルトンよりも大きくない質量を有する分子を含む、請求項1に記載の装置。
- 前記薬物は、少なくとも500,000ダルトンの質量を有する分子を含む、請求項1に記載の装置。
- 前記薬物は、タンパク質を含む、請求項1に記載の装置。
- 前記薬物は、糖を含む、請求項1に記載の装置。
- 前記糖は、約342gram/molである分子量を有する、請求項13に記載の装置。
- 前記薬物は、抗体を含む、請求項1に記載の装置。
- 前記抗体は、モノクローナル抗体である、請求項15に記載の装置。
- 前記薬物は、抗体断片を含む、請求項1に記載の装置。
- 前記薬物は、生物由来物質を含む、請求項1に記載の装置。
- 前記生物由来物質は、ワクチンを含む、請求項18に記載の装置。
- 前記生物由来物質は、血液成分を含む、請求項18に記載の装置。
- 前記生物由来物質は血液を含む、請求項18に記載の装置。
- 前記生物由来物質はアレルギー性を含む、請求項18に記載の装置。
- 前記生物由来物質は、細胞を含む、請求項18に記載の装置。
- 前記細胞は、活動的である、請求項23に記載の装置。
- 前記生物由来物質は、遺伝子を含む、請求項18に記載の装置。
- 前記生物由来物質は、組織を含む、請求項18に記載の装置。
- 前記組織は、活動的である、請求項26に記載の装置。
- 前記生物由来物質は、核酸を含む、請求項18に記載の装置。
- 前記生物由来物質は、ペプチド治療剤を含む、請求項18に記載の装置。
- 前記エンベロープは、スリーブを含む、請求項1に記載の装置。
- 前記エンベロープは、放射線検出器を含む、請求項1に記載の装置。
- 前記エンベロープは、大気を含み、前記エンベロープに含まれる前記大気は、前記エンベロープの外側にあり、かつ、前記エンベロープに隣接する大気に比較して、不活性ガスが豊富である、請求項1に記載の装置。
- 前記不活性ガスは、窒素N2を含む、請求項32に記載の装置。
- 吸水性化合物が前記エンベロープの内側に包囲されており、前記エンベロープの内側に包囲されている前記吸水性化合物の濃度は、前記吸水性化合物が、前記エンベロープの外側にあり、かつ、前記エンベロープに隣接する大気中にある場合の前記吸水性化合物の濃度よりも大きい、請求項1に記載の装置。
- 前記エンベロープ内で包囲されている気体酸素O2の濃度は、1ppm以下である、請求項1に記載の装置。
- 前記エンベロープ内に包囲されている気体水蒸気H2Oの濃度は、1ppm以下である、請求項1に記載の装置。
- 前記エンベロープは、
第1の不浸透性部材と、
第2の不浸透性部材と
を含み、
前記第1の不浸透性部材および前記第2の不浸透性部材は、相互に密閉されている、請求項1に記載の装置。 - 前記第1の不浸透性部材は、成形ポリマーを備える、請求項37に記載の装置。
- 前記第2の不浸透性部材は、ホイルを含む、請求項37に記載の装置。
- 前記第2の不浸透性部材は、商標TYVEKの下で販売されるホイルを含む、請求項39に記載の装置。
- 前記第1の不浸透性部材は、ホイルを含み、
前記第2の不浸透性部材は、ホイルを含む、請求項37に記載の装置。 - 前記第1の不浸透性部材は、シースを含み、
前記第2の不浸透性部材は、キャップを含む、請求項37に記載の装置。 - 前記キャップは、ホイルを備える、請求項42に記載の装置。
- 前記エンベロープは、ブリスターパックを含む、請求項1に記載の装置。
- 前記第1の電子ビーム減衰能力は、1よりも大きい倍数だけ前記第2の電子ビーム減衰能力よりも大きい、請求項1に記載の装置。
- 前記エンベロープは、前記第1の電子ビーム減衰能力よりも50倍小さい第3の電子ビーム減衰能力を有する、請求項1に記載の装置。
- 前記送達アセンブリは、
縦軸の周りに配置されているトロイダル状要素と、
前記縦軸の周りに配置されているシャフトと
を含む、請求項1に記載の装置。 - 前記トロイダル状要素は、前記シャフトに対して前記縦軸の周りに回転可能である、請求項47に記載の装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022163284A JP2022179650A (ja) | 2016-10-21 | 2022-10-11 | 滅菌密閉異種薬物送達デバイス |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662411182P | 2016-10-21 | 2016-10-21 | |
US62/411,182 | 2016-10-21 | ||
PCT/US2017/057525 WO2018075851A2 (en) | 2016-10-21 | 2017-10-20 | Sterile sealed heterogenous medicament delivery device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022163284A Division JP2022179650A (ja) | 2016-10-21 | 2022-10-11 | 滅菌密閉異種薬物送達デバイス |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020500046A JP2020500046A (ja) | 2020-01-09 |
JP7420554B2 true JP7420554B2 (ja) | 2024-01-23 |
Family
ID=60191581
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019521012A Active JP7420554B2 (ja) | 2016-10-21 | 2017-10-20 | 滅菌密閉異種薬物送達デバイス |
JP2022163284A Withdrawn JP2022179650A (ja) | 2016-10-21 | 2022-10-11 | 滅菌密閉異種薬物送達デバイス |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022163284A Withdrawn JP2022179650A (ja) | 2016-10-21 | 2022-10-11 | 滅菌密閉異種薬物送達デバイス |
Country Status (12)
Country | Link |
---|---|
US (1) | US11571506B2 (ja) |
EP (1) | EP3528869A2 (ja) |
JP (2) | JP7420554B2 (ja) |
KR (1) | KR20190072577A (ja) |
CN (1) | CN109862927B (ja) |
AU (1) | AU2017345693A1 (ja) |
BR (1) | BR112019004073A2 (ja) |
CA (1) | CA3039803A1 (ja) |
IL (1) | IL266094A (ja) |
MX (1) | MX2019004225A (ja) |
TW (1) | TW201818910A (ja) |
WO (1) | WO2018075851A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018089787A1 (en) | 2016-11-11 | 2018-05-17 | Insulet Corporation | Drug delivery systems with sealed and sterile fluid paths and methods of providing the same |
US11338092B1 (en) * | 2017-07-03 | 2022-05-24 | Rundeep Gadh | Electronically regulated injection pen |
US10973939B2 (en) | 2017-08-03 | 2021-04-13 | Insulet Corporation | System and method for aseptic packaging of a drug delivery device components |
US10722640B2 (en) | 2017-08-03 | 2020-07-28 | Insulet Corporation | Devices, systems, and methods of packaging for a pre-filled drug delivery device |
WO2019060839A1 (en) | 2017-09-25 | 2019-03-28 | Insulet Corporation | DRUG DELIVERY DEVICE WITH PRE-FILLED CARTRIDGE |
CN112996550B (zh) | 2018-05-01 | 2023-02-28 | Csp技术公司 | 药物输送设备及其使用和制造方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150073353A1 (en) | 2013-09-09 | 2015-03-12 | Covidien Lp | Sealed self-activating injection device for delivery of medicine from a prefilled cartridge or vial |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3359125A (en) * | 1963-04-17 | 1967-12-19 | Owens Illinois Inc | Radiation indicating glass |
US4652763A (en) | 1985-03-29 | 1987-03-24 | Energy Sciences, Inc. | Electron-beam irradiation sterilization process |
JPH03111267A (ja) * | 1989-09-27 | 1991-05-13 | Terumo Corp | 包装体 |
US5167632A (en) * | 1992-01-24 | 1992-12-01 | New Potency Products, Inc. | Syringe |
IL107038A (en) * | 1992-10-05 | 1997-04-15 | Senetek Plc | Medicament injectors and methods for injection using same |
US7329240B2 (en) | 2003-01-02 | 2008-02-12 | Meridian Medical Technologies, Inc. | Protective packaging for medicament dispenser |
US7500963B2 (en) * | 2003-07-22 | 2009-03-10 | Safety Syringes, Inc. | Systems and methods for automatic medical injection with safeguard |
US7682696B2 (en) * | 2004-09-13 | 2010-03-23 | Sabic Innovative Plastics Ip B.V. | Medical article and method of making and using the same |
FR2911071A1 (fr) | 2007-01-09 | 2008-07-11 | Becton Dickinson France Soc Pa | Procede et equipement pour la decontamination par rayonnement d'un produit tel qu'un emballage contenant des dispositifs medicaux. |
US20080183181A1 (en) * | 2007-01-30 | 2008-07-31 | Medtronic Vascular, Inc. | Enclosed Protective Packaging |
CN102112167A (zh) * | 2008-03-07 | 2011-06-29 | 医用注射器公司 | 皮内注射器及其用途 |
AT506690B1 (de) | 2008-06-16 | 2009-11-15 | Pharma Consult Ges M B H & Co | Injektionsvorrichtung |
AU2010242894A1 (en) * | 2009-04-30 | 2011-11-17 | Hyperbranch Medical Technology, Inc. | Self-contained medical applicators for surgical sealants, and methods of use thereof |
US8293173B2 (en) | 2009-04-30 | 2012-10-23 | Hitachi Zosen Corporation | Electron beam sterilization apparatus |
AR078060A1 (es) | 2009-07-14 | 2011-10-12 | Novartis Ag | Descontaminacion de superficie de contenedores previamente llenados en empaque secundario |
JP4685198B1 (ja) * | 2010-11-11 | 2011-05-18 | 株式会社アルテ | 包装用プレート、注射器保持容器及び容器兼用注射器の製造方法 |
DE102012103896A1 (de) * | 2012-05-03 | 2013-11-07 | Schott Ag | Haltestruktur zum gleichzeitigen Halten einer Mehrzahl von medizinischen oder pharmazeutischen Behältern sowie Transport- oder Verpackungsbehälter mit Selbiger |
US8727117B2 (en) * | 2012-07-16 | 2014-05-20 | Becton, Dickinson And Company | Package for syringe |
DE102012111494A1 (de) * | 2012-11-27 | 2014-05-28 | Krones Ag | Vorrichtung und Verfahren zum Sterilisieren von Behältnissen mit Röntgenstrahlungsüberwachung |
EP2968729B1 (en) * | 2013-03-14 | 2018-08-15 | Fresenius Kabi Deutschland GmbH | Packaging system for oxygen-sensitive drugs |
JP6643991B2 (ja) * | 2013-09-03 | 2020-02-12 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | キャップセンサおよび照射線センサを含む薬物送達デバイス |
-
2017
- 2017-10-20 BR BR112019004073A patent/BR112019004073A2/pt not_active Application Discontinuation
- 2017-10-20 KR KR1020197014032A patent/KR20190072577A/ko not_active Application Discontinuation
- 2017-10-20 JP JP2019521012A patent/JP7420554B2/ja active Active
- 2017-10-20 CA CA3039803A patent/CA3039803A1/en not_active Abandoned
- 2017-10-20 AU AU2017345693A patent/AU2017345693A1/en not_active Abandoned
- 2017-10-20 EP EP17791906.5A patent/EP3528869A2/en active Pending
- 2017-10-20 WO PCT/US2017/057525 patent/WO2018075851A2/en unknown
- 2017-10-20 MX MX2019004225A patent/MX2019004225A/es unknown
- 2017-10-20 TW TW106136052A patent/TW201818910A/zh unknown
- 2017-10-20 CN CN201780064821.3A patent/CN109862927B/zh active Active
-
2019
- 2019-04-15 US US16/384,410 patent/US11571506B2/en active Active
- 2019-04-17 IL IL266094A patent/IL266094A/en unknown
-
2022
- 2022-10-11 JP JP2022163284A patent/JP2022179650A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150073353A1 (en) | 2013-09-09 | 2015-03-12 | Covidien Lp | Sealed self-activating injection device for delivery of medicine from a prefilled cartridge or vial |
Also Published As
Publication number | Publication date |
---|---|
CA3039803A1 (en) | 2018-04-26 |
WO2018075851A2 (en) | 2018-04-26 |
JP2022179650A (ja) | 2022-12-02 |
WO2018075851A3 (en) | 2018-06-21 |
IL266094A (en) | 2019-06-30 |
KR20190072577A (ko) | 2019-06-25 |
AU2017345693A1 (en) | 2019-05-30 |
MX2019004225A (es) | 2019-06-10 |
CN109862927B (zh) | 2022-11-11 |
JP2020500046A (ja) | 2020-01-09 |
US20190240394A1 (en) | 2019-08-08 |
TW201818910A (zh) | 2018-06-01 |
EP3528869A2 (en) | 2019-08-28 |
CN109862927A (zh) | 2019-06-07 |
BR112019004073A2 (pt) | 2019-05-28 |
US11571506B2 (en) | 2023-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7420554B2 (ja) | 滅菌密閉異種薬物送達デバイス | |
US20230091723A1 (en) | Pharmaceutical package for ophthalmic formulations | |
CA3005117C (en) | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist | |
JP5885267B2 (ja) | 薬液投与装置、およびその作製方法 | |
JPH084613B2 (ja) | 電子ビーム照射殺菌方法 | |
EP3630062A2 (en) | Sterilizable pharmaceutical package for ophthalmic formulations | |
JP2012532715A (ja) | 二次包装における事前充填容器の表面除染 | |
JP7411543B2 (ja) | 充填済みシリンジ、および充填済みシリンジを用意する方法 | |
EP3538179B1 (en) | Drug delivery systems with sealed and sterile fluid paths and methods of providing the same | |
US20150094684A1 (en) | Apparatus for Dispensing Medicinal Fluids and Method of Making Same | |
JP2020534932A (ja) | 充填済みシリンジ、および充填済みシリンジを用意する方法 | |
WO2018215580A1 (en) | Method for sterilizing prefilled plastic syringes containing a vegf antagonist | |
KR100589674B1 (ko) | 방사성 물질 분배 장치 및 분배 방법 | |
JP3248331U (ja) | オマリズマブの新規な使用 | |
JP7408545B2 (ja) | 注射デバイスのプランジャストッパ内への超音波センサの組み込み | |
AU2015302297B2 (en) | Apparatus for dispensing medicinal fluids and method of making same | |
Golly | Keywords Packaging Syringe PFS COP/COC Glass Prefilled Syringes made of Polymer and Glass Katharina Golly· Novartis Pharma AG Correspondence: Katharina Golly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221011 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221011 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221018 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221019 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221216 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221220 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230125 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20230224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7420554 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |